Human EBV EBNA1 IgM antibody ELISA Kit

Sample

serum, plasma

Species Reactivity

Human

Detection Method

iELISA

Intended Use

Enzyme Immunoassay for the determination of EBV EBNA1 IgM in serum and plasma

Contents of Kit

Antigen-coated microplate 8 X 12 strips
Calibrator A (Negative Control) 2 ml
Calibrator B (Cut-off Standard) 2 ml
Calibrator C (Positive Control) 1 ml
IgG-RF-Sorbent 6.5 ml
HRP-conjugated antibody 20 ml (Ready-to-use)
Sample Diluent 100 ml 20X
Wash buffer 30 ml
TMB substrate 14 ml
STOP solution 14 ml

Storage

Store the unopened kit at 2-8 °C. Use the kit before expiration date.

Precision

Intra-assay and Inter-assay precision
The CV value of intra-assay precision is 7.8% and inter-assay precision is 12.1%.
Inter-lot precision
4.5-12.9%

Sensitivity

The mean MDD was 0.69 U/ml.
Assay Range: 0.69 - 60 U/mL.

General Description

In 1961 an infectious disease was identified in Uganda, which was correlated with the appearance of a defined type of tumor with children. The illness, which is found predominantly in Africa and Papua-New Guinea, was named Burkitt lymphoma from its discoverer. In 1964, Epstein, Barr and Achong characterized by electron microscopy as the causing agent a hitherto unknown virus, which belongs to the family of herpes viruses. The Epstein Barr virus is made responsible for a variety of diseases like infectious mononucleosis, Burkitt lymphoma, as well as nasopharyngeal carcinoma. In addition, a role of the virus is discussed in connection with Hodgkin´s disease. Especially with teenagers there appears a glandular fever syndrome, which is called „kissing disease". Diseases which are caused by the Epstein Barr virus are found mainly in persons with reduced immunity. For example, the virus is associated with a lymphoproliferative disease which occurs after transplantation. The immune system of such patients is usually impaired by drug therapy. Also in immune-deficient AIDS patients, there appears frequently a state where cells at the rim of the tongue are infected (oral hairy leukoplakia). Infected persons keep the Epstein-Barr virus forever in their body, they are however mostly not ill. In the developing countries practically all the people are infected, in the western world the incidence is between 80% and 90%. The transmittance occurs already during childhood, perhaps by transfer from the mother, mainly via the saliva. During the active phase of the viral cycle, the Epstein-Barr virus produces about 100 different antigens, in the inactive phase around 10. The latter comprises among others the EBV nuclear antigen EBNA-1, which is closely correlated with a past infection and an immunity. The early antigen (EA) as well as the virus capsid antigen (VCA) from the active phase are also used as diagnostic markers. In a fresh infection, IgM antibodies against VCA and EA are determined by immunofluorescence or ELISA. Later VCA IgG and afterwards EBNA-1 IgG antibodies appear. The simultaneous activation of VCA IgM and EBNA-1 IgG indicates correspondingly a reactivation of a latent EBV infection.